DEFM14A: Johnson & Johnson to Acquire Intra-Cellular Therapies for $132 Per Share in Cash

Intra-Cellular Therapies (ITI) stockholders are set to vote on a proposed merger agreement with Johnson & Johnson, where ITI would become a wholly-owned subsidiary of J&J at $132 per share.

Summary

• Intra-Cellular Therapies, Inc. (ITI) has entered into a merger agreement with Johnson & Johnson (J&J) and Fleming Merger Sub, Inc., a wholly-owned subsidiary of J&J.
• ITI stockholders will consider proposals to adopt the merger agreement, approve executive compensation related to the merger, and adjourn the stockholders meeting if necessary.
• Under the agreement, Merger Sub will merge with ITI, with ITI surviving as a wholly-owned subsidiary of J&J.
• ITI stockholders will receive $132.00 in cash per share, without interest and less any applicable withholding of taxes.
• ITI's board of directors unanimously recommends voting in favor of the merger proposal.
• The special meeting of stockholders is scheduled for March 27, 2025.
• The merger is subject to customary closing conditions, including regulatory approvals and approval by ITI's stockholders.
• The transaction is expected to close in 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining the benefits of the merger for ITI stockholders and the unanimous recommendation of the board of directors. However, there are also some risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• The merger consideration of $132.00 per share represents a significant premium for ITI stockholders.
• The ITI board of directors unanimously supports the merger.
• Johnson & Johnson has sufficient funds to complete the merger, and the merger is not subject to any financing contingencies.
• The merger provides ITI stockholders with immediate liquidity and certainty of value.

Negatives

• If the merger is not completed, ITI stockholders will not receive any payment for their shares.
• ITI will be required to pay Johnson & Johnson a termination fee of $475.5 million under certain circumstances if the merger is not completed.
• Following the merger, ITI stockholders will no longer have any equity interest in the surviving corporation.
• The merger agreement imposes restrictions on ITI's business operations prior to the completion of the merger.

Risks

• The merger is subject to regulatory approvals, which may not be obtained or may be delayed.
• The merger is subject to approval by ITI's stockholders, which may not be obtained.
• Litigation related to the transaction could arise and cause delays or expenses.
• The merger agreement may be terminated under certain circumstances.
• If the merger is not completed, ITI's stock price could decline significantly.

Future Outlook

The merger is expected to be completed in 2025, subject to customary closing conditions.

Management Comments

• On behalf of the Board of Directors, I thank you for your support and appreciate your consideration of this matter Sharon Mates, Ph.D., Chairman and Chief Executive Officer

Industry Context

The acquisition of Intra-Cellular Therapies by Johnson & Johnson reflects a broader trend of consolidation in the biopharmaceutical industry, with larger companies acquiring smaller, innovative firms to expand their pipelines and product portfolios.

Comparison to Industry Standards

• The merger consideration represents a premium of approximately 60% over ITI's closing price on January 8, 2025, which is a substantial premium compared to recent transactions in the biopharmaceutical sector.
• Comparable acquisitions, such as Pfizer's acquisition of Global Blood Therapeutics and Amgen's acquisition of Horizon Therapeutics, have also involved significant premiums, but the specific terms vary depending on the target company's pipeline, commercial products, and financial performance.
• The termination fee of $475.5 million is within the typical range for transactions of this size in the biopharmaceutical industry.

Legal Proceedings

• As of February 17, 2025, ITI has received seven letters from purported ITI stockholders demanding that the Board of Directors take action on behalf of ITI to remedy allegations regarding ITIs disclosures to stockholders with respect to various alleged omissions of material information in this proxy statement relating to the Transactions.
• ITI believes all such demands are without merit.

Stakeholder Impact

• ITI stockholders will receive $132.00 per share in cash if the merger is completed.
• ITI employees may experience changes in their compensation and benefits following the merger.
• ITI's customers and partners may be affected by the integration of ITI into Johnson & Johnson.

Next Steps

• ITI stockholders will vote on the merger agreement at a special meeting on March 27, 2025.
• The parties will seek to obtain regulatory approvals for the merger.
• If all conditions are met, the merger is expected to close in 2025.

Key Dates

Keywords

merger, acquisition, Johnson & Johnson, Intra-Cellular Therapies, stockholders, agreement, ITI, J&J